- Home
- AHCO vs EYPT Comparison
AHCO vs EYPT Comparison
Compare AHCO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHCO | EYPT |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2017 | 2005 |
Fundamental Metrics
Financial Performance| Metric | AHCO | EYPT |
|---|---|---|
| Price | $10.84 | $12.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $13.50 | ★ $31.80 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,244,857,000.00 | $7,539,000.00 |
| Revenue This Year | $9.00 | N/A |
| Revenue Next Year | $6.93 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.51 | $9.41 |
| 52 Week High | $13.43 | $19.11 |
Technical Indicators
Market Signals| Indicator | AHCO | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 55.80 | 38.96 |
| Support Level | $10.80 | $11.81 |
| Resistance Level | $12.87 | $13.32 |
| Average True Range (ATR) | 0.40 | 0.86 |
| MACD | 0.05 | -0.23 |
| Stochastic Oscillator | 55.61 | 3.07 |
Price Performance
Historical ComparisonAbout AHCO AdaptHealth Corp.
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.